Bottled Viagra
Bottled Viagra Price range: $ 114,00 through $ 324,00
Back to products
Bromhexine
Bromhexine Price range: $ 62,00 through $ 259,00

Brahmi

Price range: $ 53,00 through $ 206,00

Brahmi is a premium herbal supplement traditionally used to enhance cognitive function and support overall brain health. This natural extract is highly valued for its ability to improve memory retention and sharpen mental clarity during daily activities. As a powerful adaptogen, it helps the body manage stress effectively while promoting a balanced and calm state of mind. The antioxidant properties within Brahmi work to protect neural pathways and support long-term neurological wellness. Incorporating this time-tested botanical into your routine can help maintain peak mental performance and sustained focus.

Active substance: Brahmi
SKU: Brahmi Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Brahmi, botanically identified as Bacopa monnieri, belongs to a category of botanical extracts historically integrated into traditional Ayurvedic health systems for cognitive support. In the United States, preparations derived from this herb are classified as dietary supplements and are dispensed in accordance with applicable federal and state regulations.

While clinical research continues to evaluate the bioactivity of its constituent phytochemicals, dietary supplements containing Bacopa monnieri are not evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any medical condition. Individuals evaluating the use of this botanical product should review its clinical profile, pharmacokinetic considerations, and potential drug interactions with a qualified healthcare provider.

Basic Information

Attribute Specification
Active Ingredient Bacopa monnieri extract (standardized for bacosides)
Therapeutic / Botanical Class Herbal supplement / Botanical nootropic
Dosage Form Oral capsules, tablets, liquid extract
Route of Administration Oral
Primary Purpose Dietary support for memory retention and stress adaptation
Regulatory Status Dispensed in accordance with applicable federal and state regulations
Storage Parameters Store at controlled room temperature (59°F–86°F / 15°C–30°C)

How the Drug Works

The primary bioactive compounds identified in Bacopa monnieri are dammarane-type triterpenoid saponins, designated as bacosides (specifically bacoside A and bacoside B). The mechanism of action involves the enhancement of synaptic transmission and the modulation of key neurotransmitter systems within the central nervous system. In vitro and animal studies indicate that bacosides facilitate the repair of damaged neurons by supporting kinase activity, neuronal synthesis, and synaptic restoration.

Additionally, Bacopa monnieri exhibits significant intrinsic antioxidant activity within the frontal cortex and hippocampus. It acts by scavenging free radicals and upregulating endogenous antioxidant enzymes, including superoxide dismutase (SOD) and catalase. Pharmacological investigations also suggest minor modulation of the central cholinergic, serotonergic, and GABAergic pathways, which may contribute to its observed neuroprotective and adaptive qualities.

What It’s Used For

In dietary supplement applications within the United States market, Brahmi is utilized primarily to support cognitive function, working memory capacity, and attention span in adults. Clinical studies evaluating standardized extracts have focused on parameters such as information processing speed and spatial memory retention under acute or chronic cognitive strain.

It is also employed as an adaptogenic substance aimed at assisting the body in responding to mild physiological and psychological stress. It is important to emphasize that dietary supplement formulations of Brahmi have not received FDA approval for therapeutic clinical indications, such as Alzheimer’s disease, dementia, attention deficit hyperactivity disorder (ADHD), or clinical anxiety disorders. Usage for any neurological or psychiatric medical condition is considered non-indicated and unapproved.

Dosing Schedule

Dosing parameters for Brahmi depend heavily on the specific concentration of active bacosides present in the formulation. In clinical trials evaluating standardized Bacopa monnieri extracts, the conventional oral dosage for adults ranges from 300 mg to 450 mg per day, typically standardized to yield 20% to 50% total bacosides. When non-standardized whole-plant powder is utilized, higher mass amounts are frequently reported, though standardization provides greater dose consistency.

The daily total is generally divided into one or two administrations taken concurrently with meals. Because bacosides are lipophilic compounds, co-ingestion with dietary lipids enhances gastrointestinal absorption. Precise individual dosing schedules should be determined under the guidance of a healthcare professional, accounting for personal health history and target goals.

What Happens in the Body

Following oral administration, lipophilic saponins such as bacosides pass into the gastrointestinal tract, where partial hydrolysis occurs prior to intestinal absorption. Systematic human pharmacokinetic data regarding absolute bioavailability remain limited; however, preclinical models indicate that active metabolite fractions cross the blood-brain barrier to reach target neural tissues.

Peak systemic plasma concentrations of active saponin constituents are typically achieved within 2 to 4 hours after ingestion. Hepatic processing involves metabolic pathways mediated in part by cytochrome P450 enzyme systems, specifically CYP3A4, CYP2C9, and CYP2C19 isoforms. Elimination of transformed metabolites occurs primarily through renal excretion pathways, with a variable elimination half-life that depends on systemic metabolic rates and formulation characteristics.

What Not to Combine

Pharmacodynamic and pharmacokinetic interactions may occur when Brahmi is combined with specific pharmaceutical agents. Due to its observed cholinergic activity, Bacopa monnieri may potentiate the effects of acetylcholinesterase inhibitors (such as donepezil, rivastigmine, or galantamine) or cholinergic agonists, potentially increasing the risk of cholinergic adverse effects. Conversely, concurrent use with anticholinergic medications (such as atropine or scopolamine) may result in reduced therapeutic efficacy of either compound.

In vitro studies demonstrate potential inhibition of cytochrome P450 enzymes (CYP3A4, CYP2C9, CYP2C19), which could alter the metabolic clearance of co-administered prescription drugs processed by these pathways. Additionally, caution is advised when combining Brahmi with sedative agents, central nervous system depressants, or thyroid hormone medications, as preclinical evidence suggests potential minor alterations in thyroid hormone concentration levels.

Adverse Reactions

Clinical trial data indicate that Bacopa monnieri is generally well tolerated when administered at recommended dosages, though adverse reactions can occur. The most frequently reported adverse effects involve the gastrointestinal system. These manifestations include nausea, increased intestinal motility, abdominal cramps, and diarrhea, which are attributed to the saponin content stimulating gastrointestinal secretions and peristalsis.

Other reported secondary effects include dry mouth, fatigue, drowsiness, and occasional headache. Less common systemic events may involve minor hemodynamic changes, such as transient bradycardia. The severity and frequency of these reactions are often dose-dependent and typically resolve upon dosage reduction or discontinuation of the supplement.

Important Precautions

Special caution is warranted for individuals with underlying medical conditions prior to initiating Bacopa monnieri supplementation. Patients with pre-existing bradycardia, conduction abnormalities, or underlying cardiovascular disorders should exercise vigilance, as cholinergic upregulation can slow heart rate. Individuals with gastrointestinal tract obstruction, peptic ulcer disease, or active inflammatory bowel disorders should avoid use due to potential stimulation of gastric acid secretion and motility.

In patients with chronic pulmonary conditions, such as asthma or chronic obstructive pulmonary disease (COPD), increased bronchial secretions resulting from cholinergic pathways may exacerbate symptoms. Safety during pregnancy and lactation has not been established in rigorous human clinical trials; therefore, use in pregnant or nursing individuals is not recommended unless explicitly advised by a physician.

What to Avoid While Taking It

To minimize gastrointestinal discomfort, individuals should avoid administering Brahmi on an empty stomach. Consuming the supplement without concurrent food intake significantly increases the likelihood of nausea and abdominal cramping. Additionally, combining Brahmi with alcohol or other central nervous system depressants should be avoided due to the potential for additive sedative effects or transient drowsiness. Individuals undergoing elective surgical procedures should inform their surgical team, as supplementation should generally be discontinued at least two weeks prior to surgery to prevent unforeseen pharmacological interactions with anesthetic agents.

What You May Notice Early On

Unlike fast-acting stimulant compounds, the physiological response to Bacopa monnieri is characterized by a gradual onset. During the initial 1 to 2 weeks of consistent administration, individuals typically do not report significant changes in memory or cognitive processing. Early observations are generally limited to minor adaptive responses or mild gastrointestinal sensations as the digestive system adjusts to saponin intake.

Clinical studies evaluating cognitive end points indicate that measurable changes in memory consolidation and spatial recall generally require continuous daily administration for a period of 4 to 12 weeks. Consistency of daily dosing is therefore a critical determinant of potential systemic accumulation and bioactivity.

Storage and Expiration

Preparations containing Brahmi should be preserved in their original, tightly closed containers to protect the extract from ambient moisture and environmental humidity. Storage should occur at controlled room temperature, ideally between 59°F and 86°F (15°C to 30°C), away from direct sunlight, excessive heat, and high humidity environments such as bathrooms.

Exposure to moisture can accelerate the hydrolytic degradation of active bacoside compounds, reducing overall potency. Products must be kept out of reach of children and domestic pets. Formulations that have exceeded their printed expiration date should be disposed of in accordance with local guidance for botanical dietary supplements.

What to Ask Your Provider

Prior to integrating Brahmi into a daily regimen, individuals should prepare specific inquiries for their healthcare provider or clinical pharmacist. Essential questions include:

  • Does this botanical extract interact with any of my current prescription medications, particularly those metabolized by hepatic CYP450 enzymes?
  • Is supplementation safe given my personal cardiovascular, thyroid, and gastrointestinal medical history?
  • What specific bacoside standardization percentage is appropriate for my intended health goals?
  • How long should I continuously use this supplement before re-evaluating its utility with a clinical professional?

Common Questions

How long does it take for Brahmi to demonstrate measurable cognitive support?

Clinical research demonstrates that Bacopa monnieri operates via cumulative physiological mechanisms rather than immediate acute stimulation. Most double-blind, placebo-controlled trials evaluate cognitive metrics after 8 to 12 weeks of continuous daily administration. Individuals typically do not observe noticeable changes during the first few weeks of use, as sustained systemic tissue levels of active bacosides are necessary to support neurochemical modulation.

Can Brahmi be taken concurrently with prescription anti-anxiety medications?

Combining Brahmi with prescription anxiolytic or sedative medications (such as benzodiazepines or selective serotonin reuptake inhibitors) requires direct medical oversight. Because Bacopa monnieri exhibits mild adaptogenic and GABA-modulating properties, concurrent administration may potentially enhance central nervous system depression or sedation. A treating physician must evaluate the combined pharmacological profile to prevent unwanted additive interactions.

Why is Brahmi recommended to be consumed alongside meals containing healthy fats?

The key active constituents of Brahmi, known as bacosides, are lipophilic (fat-soluble) saponins. When administered alongside meals containing dietary fats (such as eggs, avocados, or oils), the solubility and gastrointestinal absorption of these botanical compounds are enhanced. Furthermore, co-ingestion with food mitigates the risk of direct mucosal irritation, thereby reducing common upper gastrointestinal side effects like nausea.

What should an individual do if a daily dose of Brahmi is missed?

If a routine daily dose of Brahmi is missed, the individual should take the missed dose as soon as remembered on that day, provided it is taken with food. However, if it is nearly time for the subsequent scheduled dose, the missed dose should be skipped entirely, resuming the standard schedule. Doses should never be doubled to compensate for a skipped administration, as higher acute amounts increase the risk of gastrointestinal distress.

Does Brahmi possess sedating properties that could affect motor vehicle operation?

While Brahmi is not classified as a primary sedative, some individuals experience transient drowsiness, fatigue, or decreased alertness, particularly when initiating supplementation or using higher dosages. Individuals should assess their personal physiological response to the supplement before operating heavy machinery, driving a motor vehicle, or performing tasks requiring uninterrupted mental alertness.

Source and Disclaimer

In accordance with FDA requirements, statements regarding dietary supplements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

60caps

Package

2 bottles

,

3 bottles

,

4 bottles

,

5 bottles

,

6 bottles

,

7 bottles

,

8 bottles

,

9 bottles

,

10 bottles

Ενεργός Ουσία